Table 1.

A comparison of developing treatments for acute hereditary angioedema attacks in the US

	Method of production	Mechanism of action	Half-life	Infusion method	FDA status
Berinert P®	Plasma concentrate	C1-inhibitor	36–48 h	iv	Pending FDA approval
Cinryze®	Plasma concentrate	C1-inhibitor	20–92 h	iv	Pending FDA approval
Rhucin®	Recombinant protein	C1-inhibitor	3 h	iv	Was not FDA approved
Ecallantide®	Recombinant protein	Kallikrein inhibitor	1–4 h	Subcutaneous	Pending resubmission to the FDA
Icatibant®	Synthetic peptide	Bradykinin-2 receptor antagonist	1–4 h	Subcutaneous	Was not approved by the FDA

Abbreviation: h, hours; iv, intravenous.